A Trial to Investigate Teprotumumab (High-concentration Formulation) Subcutaneous Administration in Healthy Adult Non-Japanese and Japanese Participants

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

44 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-03-24

Study Completion Date

2023-11-14

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary objective of this trial are to assess the pharmacokinetics (PK) of a single subcutaneous (SC) administration of teprotumumab high-concentration formula (HCF) in healthy adult non-Japanese and Japanese participants and to assess the PK of teprotumumab delivered by syringe pump and by an injection device in non-Japanese participants.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Phase I Trial Evaluating Safety and Tolerability of CAIV-T in Healthy Japanese Male Adults

NCT00224783

Healthy Japanese Male Adults

COMPLETED PHASE1

Safety and Immunogenicity of EXG-5003

NCT04863131

COVID-19

COMPLETED PHASE1/PHASE2

Safety and Immunogenicity of 2 Formulations of Tuberculosis Vaccine GSK692342 Given at 0,1 Months to Healthy Adults

NCT00397943

Tuberculosis

COMPLETED PHASE2

COVID-19 Subcutaneously and Orally Administered Supplemental Vaccine Boost to Enhance T Cell Protection in Those Who Have Already Received EUA S-Based Vaccines

NCT04845191

Covid19

WITHDRAWN PHASE1/PHASE2

Clinical Trial of Recombinant COVID-19 Vaccine (Sf9 Cells) in Children and Adolescents

NCT05013983

COVID-19

WITHDRAWN PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy Volunteers

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cohort 1: Teprotumumab

Non-Japanese participants will receive SC injection of teprotumumab Dose A by a syringe pump.

Group Type EXPERIMENTAL

Teprotumumab

Intervention Type DRUG

Administered as an SC injection.

Cohort 2: Teprotumumab

Japanese participants will receive SC injection of teprotumumab Dose A by a syringe pump.

Group Type EXPERIMENTAL

Teprotumumab

Intervention Type DRUG

Administered as an SC injection.

Cohort 3: Teprotumumab

Non-Japanese participants will receive SC injection of teprotumumab Dose B by an injection device.

Group Type EXPERIMENTAL

Teprotumumab

Intervention Type DRUG

Administered as an SC injection.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Teprotumumab

Administered as an SC injection.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Teprotumumab-trbw TEPEZZA HZN-001

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Participant is a healthy male or female between the ages of 18 and 55 years, inclusive, at Screening.
2. Participant has a body mass index between 18 and 30 kg/m\^2, inclusive, at Screening.
3. Participant is medically healthy, with no clinically significant medical history, physical examination, laboratory profiles, vital signs, or 12-lead ECG results at Screening, as deemed by the Principal Investigator (PI) or designee.
4. If female of childbearing potential (including those with an onset of menopause \< 2 years prior to Screening, non-therapy-induced amenorrhea for \< 12 months prior to Screening or not surgically sterile \[absence of ovaries and/or uterus\]) must have a negative serum pregnancy test at Screening and Check-in and negative urine pregnancy tests at all protocol-specified time points (ie, prior to the teprotumumab dose and throughout participation in the Follow-up Period); female participants of childbearing potential who are sexually active with a non-vasectomized male partner must agree to use 2 reliable forms of contraception during the trial, 1 of which is recommended to be hormonal, such as an oral contraceptive. Hormonal contraception must be started at least 1 full cycle prior to Day 1 and continue for 180 days after receiving the dose of teprotumumab. Highly effective contraceptive methods (with a failure rate \< 1% per year), when used consistently and correctly, include implants, injectables, combined oral contraceptives, some intrauterine devices, vasectomized partner, or sexual abstinence. Abstinence should only be used as a contraceptive method if it is in line with the participant usual and preferred lifestyle. Periodic abstinence (eg, calendar, ovulation, symptothermal, post-ovulation methods) is not an acceptable method of contraception.
5. If female, participant must agree not to donate an egg/oocyte from Day 1 until 180 days after receiving the dose of teprotumumab.
6. If male, participant must be surgically sterile for at least 6 months prior to dosing or, if sexually active with a female partner of childbearing potential, must agree to use a barrier contraceptive method from Screening through 180 days after receiving the dose of teprotumumab.
7. If male, must agree not to donate sperm from Day 1 until 180 days after receiving the dose of teprotumumab.
8. Participant has adequate venous access.
9. Participant understands the trial procedures in the ICF and is willing and able to comply with the prescribed treatment protocol and evaluations for the duration of the trial.

10. First generation Japanese healthy male or female participants must meet all of the following as confirmed by interview:

1. Descendants of 4 ethnic Japanese grandparents who were born in Japan
2. Both parents are ethnic Japanese who were born in Japan
3. Hold a Japanese passport or identity papers
4. Have lived outside Japan for less than 10 years at the time of screening and lifestyle including diet has not changed significantly since leaving Japan.

Exclusion Criteria

1. Participant has a history or presence of a clinically significant medical or psychiatric condition or disease, in the opinion of the PI or designee.
2. Participant has a history of any illness that, in the opinion of the PI or designee, might confound the results of the trial or pose an additional risk to the participant due to participation in the trial.
3. Participant has a history or presence of alcoholism (defined as \> 10 standard drinks per week, where 1 standard drink = 284 mL of full-strength \[4.9% alc/vol\] beer, 30 mL of 40% \[alc/vol\] spirit or a 100 mL glass of wine\]) or drug abuse within the 6 months prior to Day 1 dosing.
4. Participant has a history or presence of hypersensitivity or idiosyncratic reaction to components of teprotumumab or prior hypersensitivity reactions to a monoclonal antibody or history.
5. Participant has a history or presence of:

1. thyroid eye disease
2. diagnosis of autoimmune diseases
3. inflammatory bowel disease
6. Participant has an alanine transaminase or aspartate transaminase level \> 1.5 times upper limit of normal at Screening or Check-in.
7. Participant has glycated hemoglobin ≥ 6.5% and/or fasting glucose level (after at least an 8-hour fast) \> 126 mg/dL at Screening.
8. Participant has clinically significant abnormal ECG measurements at Screening or prior to teprotumumab dosing, in the opinion of the PI, or has second- or third-degree atrioventricular block or any of the following:

1. QRS \> 120 msec
2. QTcF) \> 450 msec (males) or \> 470 msec (females)
3. PR interval \> 220 msec
9. Participant has a medical condition associated with increased risk of bleeding, including history of hematological diseases such as acquired platelet disorders and coagulation disorders, including drug-induced thrombocytopenia, idiopathic thrombocytopenia or von t medication.
10. Participant has donated blood, has had significant blood loss, or has received a transfusion of any blood or blood products within 60 days prior to Day 1 or plasma donation within 7 days prior to Day 1.
11. Participant has participated in another clinical trial within 30 days (or 5 half-lives of the trial drug, whichever is longer) prior to Day 1. The 30-day (or 5 half-lives) window will be derived from the date of last dosing in the previous trial to the date of Day 1 of the current trial.
12. Participant has previous participation in a teprotumumab clinical trial or received teprotumumab or any anti-human insulin-like growth factor-1 receptor monoclonal antibody.
13. Participant has any other condition that, in the opinion of the Investigator, would preclude inclusion in the trial.
14. Participant has used any prescription (excluding hormonal birth control) or over-the-counter medications, including herbal or nutritional supplements, within 14 days before receiving the study drug. Over-the-counter use of acetaminophen (up to 2 g per day), topical eye drops, and topical creams are allowed. Use of other over-the-counter medications may be allowed at the discretion of Investigator with approval from the Medical Monitor.

Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes